Mayne Pharma Group Limited (MAYNF)
USD 4.25
(-2.3%)
USD 4.25
(-2.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 688.98 Million AUD | 12.25% |
| 2023 | 613.77 Million AUD | -16.01% |
| 2022 | 730.8 Million AUD | 5.67% |
| 2021 | 691.6 Million AUD | -11.66% |
| 2020 | 782.86 Million AUD | 25.81% |
| 2019 | 622.25 Million AUD | 4.52% |
| 2018 | 595.35 Million AUD | -1.19% |
| 2017 | 602.49 Million AUD | -48.99% |
| 2016 | 1.18 Billion AUD | 471.32% |
| 2015 | 206.74 Million AUD | 94.04% |
| 2014 | 106.54 Million AUD | -5.29% |
| 2013 | 112.5 Million AUD | 382.16% |
| 2012 | 23.33 Million AUD | -20.91% |
| 2011 | 29.5 Million AUD | -35.3% |
| 2010 | 45.59 Million AUD | 13654.27% |
| 2009 | 331.53 Thousand AUD | 30.09% |
| 2008 | 254.85 Thousand AUD | -74.42% |
| 2007 | 996.15 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 688.98 Million AUD | 13.71% |
| 2024 Q4 | 688.98 Million AUD | 0.0% |
| 2024 Q2 | 605.91 Million AUD | 0.17% |
| 2024 FY | 689.04 Million AUD | 12.26% |
| 2024 Q1 | 604.87 Million AUD | -17.23% |
| 2023 Q2 | 695.54 Million AUD | 0.02% |
| 2023 FY | 613.77 Million AUD | -16.01% |
| 2023 Q1 | 695.39 Million AUD | -6.78% |
| 2023 Q4 | 730.8 Million AUD | 19.22% |
| 2023 Q3 | 612.99 Million AUD | -11.87% |
| 2022 Q2 | 733.51 Million AUD | 2.02% |
| 2022 Q4 | 745.99 Million AUD | -0.49% |
| 2022 FY | 730.8 Million AUD | 5.67% |
| 2022 Q3 | 749.69 Million AUD | 2.21% |
| 2022 Q1 | 718.99 Million AUD | 3.96% |
| 2021 Q1 | 712.46 Million AUD | -8.99% |
| 2021 FY | 691.6 Million AUD | -11.66% |
| 2021 Q2 | 726.85 Million AUD | 2.02% |
| 2021 Q4 | 691.6 Million AUD | 0.0% |
| 2021 Q3 | 691.6 Million AUD | -4.85% |
| 2020 Q4 | 782.86 Million AUD | 0.0% |
| 2020 FY | 782.86 Million AUD | 25.81% |
| 2020 Q2 | 791.25 Million AUD | 2.35% |
| 2020 Q3 | 782.86 Million AUD | -1.06% |
| 2020 Q1 | 773.07 Million AUD | 24.24% |
| 2019 Q4 | 622.25 Million AUD | -0.0% |
| 2019 FY | 622.25 Million AUD | 4.52% |
| 2019 Q3 | 622.26 Million AUD | -12.98% |
| 2019 Q1 | 715.08 Million AUD | 20.11% |
| 2019 Q2 | 715.08 Million AUD | 0.0% |
| 2018 Q4 | 595.35 Million AUD | -0.0% |
| 2018 Q2 | 596.85 Million AUD | 0.0% |
| 2018 FY | 595.35 Million AUD | -1.19% |
| 2018 Q1 | 596.85 Million AUD | -0.94% |
| 2018 Q3 | 595.35 Million AUD | -0.25% |
| 2017 Q3 | 595.61 Million AUD | 3.18% |
| 2017 Q2 | 577.28 Million AUD | 0.0% |
| 2017 Q4 | 602.49 Million AUD | 1.16% |
| 2017 Q1 | 577.28 Million AUD | -51.13% |
| 2017 FY | 602.49 Million AUD | -48.99% |
| 2016 FY | 1.18 Billion AUD | 471.32% |
| 2016 Q1 | 249.05 Million AUD | 20.47% |
| 2016 Q4 | 1.18 Billion AUD | 2.75% |
| 2016 Q3 | 1.14 Billion AUD | 361.57% |
| 2016 Q2 | 249.05 Million AUD | 0.0% |
| 2015 Q3 | 206.74 Million AUD | 47.74% |
| 2015 Q2 | 139.93 Million AUD | 0.0% |
| 2015 FY | 206.74 Million AUD | 94.04% |
| 2015 Q4 | 206.74 Million AUD | 0.0% |
| 2015 Q1 | 139.93 Million AUD | 31.34% |
| 2014 FY | 106.54 Million AUD | -5.29% |
| 2014 Q2 | 122.82 Million AUD | 0.0% |
| 2014 Q3 | 106.54 Million AUD | -13.25% |
| 2014 Q4 | 106.54 Million AUD | 0.0% |
| 2014 Q1 | 122.82 Million AUD | 9.18% |
| 2013 FY | 112.5 Million AUD | 382.16% |
| 2013 Q3 | 112.5 Million AUD | 0.0% |
| 2013 Q4 | 112.5 Million AUD | 0.0% |
| 2012 Q4 | 23.33 Million AUD | 0.0% |
| 2012 FY | 23.33 Million AUD | -20.91% |
| 2011 FY | 29.5 Million AUD | -35.3% |
| 2011 Q4 | 29.5 Million AUD | 0.0% |
| 2010 Q4 | 45.59 Million AUD | 0.0% |
| 2010 FY | 45.59 Million AUD | 13654.27% |
| 2009 Q4 | 331.53 Thousand AUD | 0.0% |
| 2009 FY | 331.53 Thousand AUD | 30.09% |
| 2008 FY | 254.85 Thousand AUD | -74.42% |
| 2008 Q4 | 254.85 Thousand AUD | 0.0% |
| 2007 FY | 996.15 Thousand AUD | 0.0% |
| 2007 Q4 | 996.15 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | 98.886% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 98.951% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | 55.255% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -918.808% |
| Novartis AG | 53.19 Billion USD | 98.705% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -169.199% |